RMD: Rounding Bottom detected on 28 Oct 2026

RMD is forming a rounding bottom pattern with a solid overall score of 69.0 and 64.36% win probability. Structure (13.0/15) and breakout quality (13.0/13) are both strong, though volume support is moderate at 9.0/12. Current price of $250.80 sits 8.93% below the 52-week high and 39.53% above the 52-week low, testing key resistance at $261.37. The setup suggests momentum: RSI at 72.07 signals overbought conditions, MACD histogram is positive at 1.7144, and Bollinger Band position at 0.815 indicates price in upper band range. Recent volume of 936,664 shares runs 16% below the 20-day average (1,116,808), a minor weakness in confirmation.

Resmed is scheduled to release 1Q FY2027 earnings on October 29, 2026, after market close—just one day after this pattern detection, creating an imminent earnings catalyst. FY26 revenue reached $5.65 billion, up 10% year-over-year, and non-GAAP EPS grew 17% in FY26 with over $1.6 billion in free cash flow generated. Recent product expansion supports growth momentum: Resmed introduced the AirTouch F40 fabric CPAP mask in the United States in October 2026, and the company acquired Noctrix Health in June 2026, expanding its clinical sleep health portfolio into restless legs syndrome treatment. The healthcare sector regime is bullish (score 0.9), and Resmed returned over $1 billion to shareholders in FY26 through dividends and repurchases, up 70% from prior year, reflecting strong cash generation and management confidence.

A successful breakout above resistance at $261.37 would target the conservative measure of $265.47—a modest 1.8% upside from current levels, though the rounding bottom structure typically extends further. The 64.36% win probability indicates above-average odds for pattern completion. Volume confirmation is critical: current relative volume of 0.84 (16% below average) suggests breakout conviction could improve with elevated volume on breach of $261.37. Invalidation occurs decisively below key support at $179.75, representing a 28.3% downside loss from current price. The pattern's validity depends on holding this support level and confirming the bottom structure in coming sessions.

RSI at 72.07 signals overbought territory (>70), warning that momentum may face mean-reversion pressure near resistance. The imminent 1Q FY27 earnings release tomorrow (Oct 29, 2026) carries substantial execution risk—if results disappoint or guidance is cut despite strong FY26 performance and recent product launches, the setup could gap lower and violate key support. Volume remains below average (0.84 relative), reducing breakout conviction and increasing risk of false breakout. While beta is low at 0.62 (defensive), the healthcare sector's bullish regime (0.9) could reverse if macro headwinds emerge. Volatility at 20.1% is elevated relative to the ATR of 2.23%, suggesting price swings could test support suddenly if earnings disappoint or broader risk-off sentiment develops in healthcare equities.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.